Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged 55 years with hematological malignancies

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L et al. Quality of life and outcomes in patients60 years of age after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2014; 49: 1426–1431.

    CAS  Article  Google Scholar 

  2. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    CAS  Article  Google Scholar 

  3. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637.

    CAS  Article  Google Scholar 

  4. Terakura S, Atsuta Y, Sawa M, Ohashi H, Kato T, Nishiwaki S et al. A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. Ann Oncol 2011; 22: 1865–1871.

    CAS  Article  Google Scholar 

  5. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052–3059.

    CAS  Article  Google Scholar 

  6. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007; 86: 269–274.

    Article  Google Scholar 

  7. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367–369.

    Article  Google Scholar 

  8. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123: 3664–3671.

    CAS  Article  Google Scholar 

  9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  10. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.

    CAS  Article  Google Scholar 

  11. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Samuel S, Elad S et al. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant 2004; 34: 155–159.

    CAS  Article  Google Scholar 

  12. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P et al. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 1453–1458.

    CAS  Article  Google Scholar 

  13. Gahrton G . Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Pract Res Clin Haematol 2007; 20: 219–229.

    Article  Google Scholar 

  14. Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW . Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 2000; 26: 601–605.

    CAS  Article  Google Scholar 

  15. DiMartini A, Fontes P, Dew MA, Lotrich FE, de Vera M . Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity. Liver Transpl 2008; 14: 815–822.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank all of the physicians and staff at the cooperating centers for contributing patient data for this study.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to K Miyao.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Miyao, K., Sawa, M., Kuwatsuka, Y. et al. Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged 55 years with hematological malignancies. Bone Marrow Transplant 51, 157–160 (2016). https://doi.org/10.1038/bmt.2015.235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.235

Further reading

Search

Quick links